Broken String Biosciences
  • Company
    • About us
    • Careers
    • Contact us
  • Technology
  • Resources
    • Publications
    • Webinars
  • News & Events

  • Broken String Biosciences Launches Catalyst Program to Shorten Gene Editing Therapy Development by Months

    Broken String Biosciences Launches Catalyst Program to Shorten Gene Editing Therapy Development by Months

    BOSTON, MA and Cambridge, UK, February 6, 2025 – Broken String Biosciences (“Broken String”), a leader in advancing gene editing safety, today opened its Catalyst Early Access Program (EAP) for developers of gene-edited therapies that allow for the detection of on- and off-target edits at high resolution, in days, in their own labs. The program…

    February 6, 2025
  • Broken String Biosciences appoints Laurence Reid and Brad Crutchfield to its Board of Directors 

    Broken String Biosciences appoints Laurence Reid and Brad Crutchfield to its Board of Directors 

    Cambridge, UK, 23 September 2024: Broken String Biosciences (“Broken String”), a genomics company enabling development of the next generation of more precise, safe, and effective cell and gene therapies, today announced the appointments of Laurence Reid, PhD, as Chairman, and Brad Crutchfield as Non-Executive Director (NED) of its Board of Directors.  Bringing extensive commercial and leadership expertise to the Board, Laurence…

    September 23, 2024
  • Broken String Biosciences appoints Steve Becker as Chief Commercial Officer 

    Broken String Biosciences appoints Steve Becker as Chief Commercial Officer 

    Appointment brings extensive experience to lead commercial operations and accelerate growth in key global markets Cambridge, UK, 24 July 2024: Broken String Biosciences (“Broken String”), a genomics company driving development of the next generation of more precise, safe, and effective cell and gene therapies, today announced it has appointed Steve Becker as Chief Commercial Officer. An experienced global life sciences executive,…

    July 24, 2024
  • Broken String Biosciences joins Campus

    Broken String Biosciences joins Campus

    Cell & gene therapies based on genome editing technologies such as CRISPR-Cas9 are positioned to become a new generation of transformative therapeutics, with the ability to correct disease at the genetic level. Because they directly alter our DNA and have the propensity to go ‘off-target’, assessing whether these therapies are safe for patients is extremely…

    March 3, 2022
  • Genomics company Broken String Biosciences expands presence within the Cambridge cluster with new laboratory at Chesterford Research Park

    Genomics company Broken String Biosciences expands presence within the Cambridge cluster with new laboratory at Chesterford Research Park

    Chesterford Research Park is delighted to welcome Broken String Biosciences to the Park’s eminent Science Village. Aiming to develop safer cell and gene therapies by assessing the stability of the genome, Broken String Biosciences is leveraging novel genomic sequencing approaches to build a technology platform that will drive the development of CRISPR cell and gene therapies that…

    February 28, 2022
Broken String Biosciences

Broken String Biosciences
Unit AB3-04, Level 3
BioData Innovation Centre
Wellcome Genome Campus
Hinxton
Cambridge, CB10 1DR

VAT number: GB 372 333 704

  • X
  • LinkedIn Profile

info@brokenstringbio.com
+44(0)1223 786 071

© 2025 Broken String Biosciences – All rights reserved

Website by KISS

  • Company
  • Technology
  • News & events
  • Our team
  • Careers
  • Contact us
  • Privacy Policy
  • Terms & Conditions
bsi ISO 9001 Quality Management Systems
Cyber Essentials Certified